After analysing the immunohistochemical results, RIPK2 expression was only medium–high in Endometrial cancer (8/12 patients), Lymphoma (6/11 patients) and Prostate cancer (6/12 patients), and the proportion of medium–high expression of RIPK2 in endometrial cancer, lymphoma and prostate cancer tissues was higher than that of low or negative expression (Fig. 2). Here, RIPK2 is linked to prostate cancer.